Peregrine Pharmaceuticals is spreading its wings and taking flight to attack and kill its prey: cancer and viral infections. Its clinical pipeline includes bavituximab being tested to treat pancreatic and liver cancer, as well as hepatitis C. Peregrine's other candidate, Cotara, attacks tumors from the inside out: the monoclonal antibody is loaded with radioisotopes and attaches itself to the DNA of dead and dying cells inside cancerous tissue, and then the radioisotopes bombard nearby tumor cells without harming healthy tissue. Cotara is in clinical trials for for the treatment of glioblastoma multiforme, a deadly brain cancer.